Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03310580 · ClinicalTrials.gov registry record · Phase 2
Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension
A Phase 2 study of Primary Open Angle Glaucoma or Ocular Hypertension, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 20
- Study locations
NCT03310580: Completed Phase 2 study of Primary Open Angle Glaucoma or Ocular Hypertension, sponsored by Aerie Pharmaceuticals.
NCT03310580 is a Phase 2 study of Primary Open Angle Glaucoma or Ocular Hypertension that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 42 participants, below the 50-participant average among 3 other Primary Open Angle Glaucoma or Ocular Hypertension trials with a reported enrollment target (16% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03310580, a Phase 2 study of Primary Open Angle Glaucoma or Ocular Hypertension, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 20
- Study locations
Study Summary
To test the safety and effectiveness of AR-13324 0.02% and 0.04% ophthalmic solution relative to placebo in Japanese/Japanese-American subjects with open-angle glaucoma or ocular hypertension in US.
Primary Outcome
Mean diurnal intraocular pressure (IOP) at week 4, measured by Goldman Applanation Tonometry (GAT).
Conditions Studied
Interventions
- DRUG AR-13324 Ophthalmic Solution 0.02%
- DRUG AR-13324 Ophthalmic Solution 0.04%
- DRUG AR-13324 Ophthalmic Solution Placebo
Study Locations (20)
California
- Milton M. Hom, OD FAAO FACAAISc - Azusa
- Havana Research Institute - Burbank
- Global Research Management - Glendale
- Southern California Eye Physicians & Surgeons - Los Alamitos
- East West Eye Institute - Los Angeles
- USC Roski Eye Institute University of Souther California - Los Angeles
- Global Research Foundation - Los Angeles
- The Eye Research Foundation - Newport Beach
- Southern California Eye Physicians Surgeons - Pasadena
- North Bay Eye Associates Inc. - Petaluma
- Martel Eye - Rancho Cordova
- University of California - San Diego
- AdvanceMed Clinical Research - San Diego
- Glaucoma Center of San Francisco - San Francisco
- Samsum Clinic - Santa Barbara
Arizona
- Arizona Eye Center - Chandler
- Arizona Glaucoma Specialists - Phoenix
Colorado
- MCB Clinical Research Centers LLC - Colorado Springs
Georgia
- Clayton Eye Clinical Research, LLC - Morrow
Hawaii
- Jenkins Eye Care - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2017-11-15 |
| Est. Completion | 2018-10-25 |
| Phase | Phase 2 |
What the finished NCT03310580 record still lists
NCT03310580 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 50-participant average among 3 other Primary Open Angle Glaucoma or Ocular Hypertension trials with a reported enrollment target (16% lower).
The record links to 1 condition, with Primary Open Angle Glaucoma or Ocular Hypertension appearing as the primary indexed condition, and to 3 interventions - of which AR-13324 Ophthalmic Solution 0.02% is the first listed.
NCT03310580 names 20 study sites across 5 states, led by California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT03310580 about?
NCT03310580 is a clinical study titled "Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension". To test the safety and effectiveness of AR-13324 0.02% and 0.04% ophthalmic solution relative to placebo in Japanese/Japanese-American subjects with open-angle glaucoma or ocular hypertension in US.
What is the current status of trial NCT03310580?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2017-11-15. Estimated completion is 2018-10-25.
What conditions does trial NCT03310580 study?
This clinical trial studies the following conditions: Primary Open Angle Glaucoma or Ocular Hypertension.
What interventions are being tested in trial NCT03310580?
The interventions under investigation include: AR-13324 Ophthalmic Solution 0.02% (DRUG), AR-13324 Ophthalmic Solution 0.04% (DRUG), AR-13324 Ophthalmic Solution Placebo (DRUG).
Who is sponsoring clinical trial NCT03310580?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03310580 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Open Angle Glaucoma or Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
COMPLETED · Phase 2
-
A Prospective Study on the Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in Achieving >20% Intraocular Pressure (IOP) Reduction Without Medications at 6 Months in Naive, Untreated Glaucoma Patients
RECRUITING
-
Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI